Hydroxychloroquine for Early Treatment of Adults with Mild Coronavirus Disease 2019: A Randomized, Controlled Trial

Clinical Infectious Diseases

Volumn 73, Issue 11, 2021, Pages E4073-E4081

  Mitjà, Oriol ^a,b,c   Corbacho Monné, Marc ^a,d   Ubals, Maria ^b,d   Tebé, Cristian ^e   Peñafiel, Judith ^e   Tobias, Aurelio ^f   Ballana, Ester ^g   Alemany, Andrea ^a   Riera Martí, Núria ^a   Pérez, Carla A ^a   Suñer, Clara ^a   Laporte, Pep ^a   Admella, Pol ^a   Mitjà, Jordi ^a   Clua, Mireia ^a   Bertran, Laia ^a   Sarquella, Maria ^a   Gavilán, Sergi ^a   Ara, Jordi ^b   Argimon, Josep M ^h   Casabona, Jordi ^i,j   Cuatrecasas, Gabriel ^k   Cañadas, Paz ^l   Elizalde Torrent, Aleix ^g   Fabregat, Robert ^m   Farré, Magí ^b   Forcada, Anna ^h   Flores Mateo, Gemma ⁿ   Muntada, Esteve ⁱ   Nadal, Núria ^h   Narejos, Silvia ^o   Nieto, Aroa ^a   Prat, Nuria ^h   Puig, Jordi ^a   Quiñones, Carles ^b   Reyes Ureña, Juliana ^i,j   Ramírez Viaplana, Ferran ^a   Ruiz, Lidia ^g   Riveira Muñoz, Eva ^g   Sierra, Alba ^a   Velasco, César ^p   Vivanco Hidalgo, Rosa Maria ^p   Sentís, Alexis ⁱ   G Beiras, Camila ^a   Clotet, Bonaventura ^a,g,q   Vall Mayans, Martí ^a,b   more..

^a Fight AIDS and Infectious Diseases Foundation   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Lihir Medical Centre International SOS   (Papua New Guinea)

^d UNIVERSITY OF BARCELONA   (Spain)

^e BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^f INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

^g Research Foundation Germans Trias i Pujol   (Spain)

^h INSTITUT CATALÀ DE LA SALUT   (Spain)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^k Centre d'Atenció Primària CAP Sardenya   (Spain)

^l SYNLAB International Group   (Spain)

^m GENERALITAT DE CATALUNYA   (Spain)

ⁿ Unidad Docente Xarxa Sanitària I Social Sant Pau I Santa Tecla   (Spain)

^o Entitat de Base Asociativa Centelles Atenció Primària   (Spain)

^p Agència de Qualitat i Avaluació Sanitàries de Catalunya   (Spain)

^q UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

more..

Author keywords

COVID 19; hydroxychloroquine; randomized controlled trial; SARS CoV 2; therapy

Indexed keywords

HYDROXYCHLOROQUINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CATALONIA; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DIARRHEA; DISEASE EXACERBATION; DROWSINESS; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; INVASIVE VENTILATION; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MULTICENTER STUDY; NASOPHARYNGEAL SWAB; NAUSEA; OPEN STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SPAIN; VIRUS LOAD; VIRUS SHEDDING; DRUG THERAPY; TREATMENT OUTCOME;

ADULT; COVID-19; HUMANS; HYDROXYCHLOROQUINE; SARS-COV-2; TREATMENT OUTCOME;

EID: 85122546667     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa1009     Document Type: Article

References (28)

1. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14:58-60.
2. European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. 2020. Available at: https://www.ema.europa.eu/en/documents/press-release/COVID-19-chloroquinehydroxychloroquine-only-be-used-clinical-Trials-emergency-use-programmes-en.pdf. Accessed 22 June 2020.
3. Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020; 369:m1335.
4. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006; 6:67-9.
5. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42:145-53.
6. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269-71.
7. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; doi: 10.1093/cid/ ciaa237.
8. Fan J, Zhang X, Liu J, et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: A critical step in treating COVID-19 patients. Clin Infect Dis 2020; doi: 10.1093/cid/ciaa623.
9. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020; doi: 10.1101/2020.03.22.20040758.
10. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369:m1849.
11. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50:384.
12. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56:105949.
13. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis 2020; 34:101663.
14. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 382:2411-18.
15. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14:72-3.
16. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020; doi:10.1001/jama.2020.8630.
17. Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; doi:10.1016/ S1473-3099(20)30483-7.
18. Catalan Ministry of Health. Catalan epidemiological surveillance system. Available at: http://salutpublica.gencat.cat/ca/ambits/vigilancia-salut-publica/. Accessed 28 March 2020.
19. De Meyer S, Bojkova D, Cinatl J, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. Int J Infect Dis 2020; 97:7-10.
20. Johnson & Johnson. Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2. 2020. Available at: https://www.jnj.com/lack-ofevidence-to-support-darunavir-based-hiv-Treatments-for-coronavirus. Accessed 1 June 2020.
21. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382:1787-99.
22. Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-Time RT-PCR diagnostic panel. 2020. Available at: https://www.fda. gov/media/134922/download. Accessed 21 May 2020.
23. To KK-WW, Tsang OT-YY, Leung W-SS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. Lancet Infect Dis 2020; 20:565-74.
24. Gupta SB, Jacobson LP, Margolick JB, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 2007; 195:546-50.
25. R Core Team. R: A language and environment for statistical computing. 2017. Available at: https://www.r-project.org. Accessed 25 May 2020.
26. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; doi: 10.1001/jamacardio.2020.1834.
27. Lin S, Shen R, Guo X. Molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to Wuhan pneumonia coronavirus proteases. bioRxiv 2020; doi: 10.1101/2020.01.31.929695.
28. Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: A systematic review. Infect Prev Pract 2020; 2:100061.